MCL1 and mantle cell lymphoma: HHT in combination with bortezomib exert cytotoxic effects against diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells by myeloid leukemia cell differentiation protein-1 (MCL-1) down-regulation, Phorbol-12-Myristate-13-Acetate-Induced Protein 1 (PMAIP1) up-regulation, and Bcl-2 homologous antagonist/killer (BAK) activation (Nguyen et al., 2018).